$COAG earnings report

Hemab reports Q3 2026 net loss of $27.3 million ($0.58 per share) as it starts the SOLARA Phase 3 trial and reports first FVIID clinical data; cash and marketable securities fell to $430.2 million. AlphAI read Hemab Therapeutics Holdings's Q3 FY2026 filing as mixed.

Q3 FY2026

AlphAI · Earnings readCOAG · Q3 2026 · ended 2026-09-30

Hemab reports Q3 2026 net loss of $27.3 million ($0.58 per share) as it starts the SOLARA Phase 3 trial and reports first FVIID clinical data; cash and marketable securities fell to $430.2 million

→Mixed quarter

The filing shows clinical progress (Phase 3 SOLARA initiated, first HMB-003 participant dosed, first sutacimig FVIID clinical data) and cash runway stated into 2029. Operating expenses rose sharply versus the prior-year quarter, cash and marketable securities declined from June 30, 2026, and the release discloses that the FDA recommended a randomized design for SOLARA that the company did not adopt. No guidance or consensus is provided to benchmark results against.

EPS · GAAP
$(0.58)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses (three months ended Sept 30)GAAP$24.64M––
General and administrative expenses (three months ended Sept 30)GAAP$5.12M––
Total operating expenses (three months ended Sept 30)GAAP$29.76M––
Loss from operations (three months ended Sept 30)GAAP−$29.76M––
Interest income (three months ended Sept 30)GAAP$3.38M––
Other income (expense), net (three months ended Sept 30)GAAP−$237K––
Total other income, net (three months ended Sept 30)GAAP$3.15M––
Loss before income tax expense (three months ended Sept 30)GAAP−$26.61M––
Income tax (expense) benefit (three months ended Sept 30)GAAP−$693K––
Net loss (three months ended Sept 30)GAAP−$27.30M––
Net loss per share, basic and diluted (three months ended Sept 30)GAAP$(0.58)––
Research and development expenses (nine months ended Sept 30)GAAP$64.44M––
General and administrative expenses (nine months ended Sept 30)GAAP$15.01M––
Total operating expenses (nine months ended Sept 30)GAAP$79.45M––
Loss from operations (nine months ended Sept 30)GAAP−$79.45M––
Interest income (nine months ended Sept 30)GAAP$7.46M––
Other income (expense), net (nine months ended Sept 30)GAAP−$1.35M––
Total other income, net (nine months ended Sept 30)GAAP$6.11M––
Loss before income tax expense (nine months ended Sept 30)GAAP−$73.34M––
Income tax (expense) benefit (nine months ended Sept 30)GAAP−$802K––
Net loss (nine months ended Sept 30)GAAP−$74.14M––
Net loss per share, basic and diluted (nine months ended Sept 30)GAAP$(2.84)––
Total comprehensive loss (three months ended Sept 30)GAAP−$27.21M––
Total comprehensive loss (nine months ended Sept 30)GAAP−$76.97M––
Cash, cash equivalents and marketable securities (as of Sept 30, 2026)GAAP$430.2M––
Net cash used in operating activities (nine months ended Sept 30)GAAP−$72.51M–$(27,751) thousand
Net cash (used in) provided by investing activities (nine months ended Sept 30)GAAP−$93.18M–$(108,688) thousand
Net cash provided by (used in) financing activities (nine months ended Sept 30)GAAP$317.2M–$317,255 thousand
Net increase (decrease) in cash and cash equivalents (nine months ended Sept 30)GAAP$151.2M–$180,517 thousand
Total assets (as of Sept 30, 2026)GAAP$442.7M––
Total liabilities (as of Sept 30, 2026)GAAP$13.44M––
Total stockholders' equity (deficit) (as of Sept 30, 2026)GAAP$429.3M––
Cash and cash equivalents (as of Sept 30, 2026)GAAP$239.1M––
Marketable securities (as of Sept 30, 2026)GAAP$191.1M––

Capital returns

  • The filing reports no share repurchases and no dividends for the periods presented.
  • Financing cash flow for the nine months ended Sept 30, 2026 was $317,166 thousand, which the filing does not attribute to a specific transaction in this release beyond the initial public offering and preferred stock conversion referenced in the net loss per share discussion.

What drove it

  • Company explanation for higher R&D expenses: costs related to advancement of clinical programs, increases in personnel-related expenses and equity-based compensation, and discovery and consulting fees related to company growth to support program advancement.
  • Company explanation for higher G&A expenses: professional services, equity-based compensation and other costs associated with operating as a public company.
  • Company explanation for the lower net loss per share: the increase in weighted-average shares outstanding following the initial public offering and the conversion of preferred stock into common stock in May 2026.
  • Company explanation for the decline in cash and marketable securities: primarily cash used in operating activities.
  • Clinical and pipeline activity in the period: SOLARA Phase 3 trial of sutacimig in GT initiated (first participants consented, run-in period scheduled for Q4 2026); first participant dosed in the Phase 1 trial of HMB-003 (September); first clinical data from the single ascending dose cohort of the sutacimig FVIID Phase 2b trial announced (November).

Concerns

  • Net loss for the three months ended Sept 30, 2026 was $(27,304) thousand, compared with $(17,065) thousand in the prior-year quarter, and for the nine months $(74,141) thousand compared with $(44,580) thousand.
  • Total operating expenses for the three months were $29,758 thousand compared with $17,055 thousand in the prior-year quarter.
  • The FDA recommended that the company consider a randomized controlled design for SOLARA. The company has determined to proceed with a single-arm, intra-participant design, and the release states the FDA may not accept this design, may require additional trials, or the company's decision could result in delays, added costs or inability to obtain approval.
  • Cash, cash equivalents and marketable securities declined from $457.5 million at June 30, 2026 to $430.2 million at September 30, 2026.
  • Clinical data for HMB-002 and sutacimig FVIID are described by the company as preliminary or descriptive; the VELORA single ascending dose portion was not designed to measure efficacy, and the FVIID data cover two participants.

What to watch

  • SOLARA run-in period start (fourth quarter 2026) and subsequent enrollment of approximately 75 participants aged 12 to 70 years.
  • Updated sutacimig FVIID data for all dosed participants at the 68th ASH Annual Meeting, poster on December 14, 2026.
  • HMB-003 preclinical poster at the 68th ASH Annual Meeting on December 13, 2026, and initial clinical data from the Phase 1 trial expected in mid-2027.
  • Additional HMB-002 data from VELORA Pioneer at the 20th EAHAD Congress in February 2027.
  • Operating expense trajectory and cash burn against the company's stated runway into 2029.
  • Regulatory feedback on the single-arm SOLARA design, given the FDA's recommendation for a randomized design.

Balance sheet and cash flow

  • Cash, cash equivalents and marketable securities totaled $430.2 million as of September 30, 2026, compared to $457.5 million as of June 30, 2026. The company states the decrease primarily reflects cash used in operating activities.
  • The company believes its current cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditure requirements into 2029.
  • Cash and cash equivalents were $239,149 thousand and marketable securities were $191,089 thousand as of September 30, 2026.
  • Total stockholders' equity was $429,269 thousand as of September 30, 2026, compared with a deficit of $(176,635) thousand as of December 31, 2025. The filing states that convertible preferred stock and convertible preference shares were $360,168 thousand at December 31, 2025 and nil at September 30, 2026.
  • Net cash used in operating activities was $(72,512) thousand for the nine months ended September 30, 2026, compared with $(44,761) thousand in the prior-year period.

Analysis

Hemab reported a third-quarter 2026 net loss of $(27,304) thousand, or $(0.58) per share, against a net loss of $(17,065) thousand in the prior-year quarter. Total operating expenses rose to $29,758 thousand from $17,055 thousand, with research and development at $24,639 thousand (prior year $14,555 thousand) and general and administrative at $5,119 thousand (prior year $2,500 thousand). Interest income increased to $3,384 thousand from $215 thousand, which partly offset the operating loss within other income, net of $3,147 thousand. Nine-month figures show the same direction: total operating expenses of $79,449 thousand against $49,672 thousand, and a net loss of $(74,141) thousand against $(44,580) thousand. The release provides no revenue lines, so the results describe a clinical-stage cost base with no reported product revenue.

The company attributes the higher R&D spend to clinical program advancement, personnel and equity-based compensation, and discovery and consulting fees, and the higher G&A to professional services, equity compensation and public company costs. It also attributes the lower net loss per share, which compares $(0.58) with $(18.04) in the prior-year quarter, to the larger weighted-average share count after the initial public offering and the May 2026 conversion of preferred stock. The release does not print a prior-year share count alongside the per-share figure, so the per-share comparison should be read with that explanation in mind.

On the balance sheet, cash, cash equivalents and marketable securities were $430.2 million at September 30, 2026, down from $457.5 million at June 30, 2026. The company says the decline primarily reflects operating cash use, and that current resources will fund operating expenses and capital expenditure into 2029. Nine-month operating cash outflow was $(72,512) thousand against $(44,761) thousand a year earlier. Financing inflows of $317,166 thousand over the nine months reflect the offering period, and total stockholders' equity moved to $429,269 thousand from a deficit of $(176,635) thousand at December 31, 2025.

On the pipeline, the period contained the start of the SOLARA Phase 3 trial of sutacimig in GT, first HMB-003 dosing in a Phase 1 trial, and first FVIID clinical data. The FDA recommended a randomized design for SOLARA, and the company has chosen a single-arm intra-participant design, which the release acknowledges could affect the timeline, cost or approvability. The company gave no numerical financial guidance in this release, so there is no outlook to measure the quarter against. The figures that deserve attention are the widening operating loss, the $27.1 million fall in cash and marketable securities from June 30 to September 30 as printed, and the regulatory path for SOLARA.

Management, verbatim

We are excited to have started our Phase 3 study in Glanzmann thrombasthenia, transitioning Hemab to a biotech company with clinical stage programs ranging from Phase 1 to Phase 3 across our portfolio.

Benny Sørensen, MD, PhD, Chief Executive Officer, Hemab Therapeutics

We are also excited to have dosed our first participant in the Phase 1 trial of HMB-003 in heavy menstrual bleeding, and look forward to sharing additional preclinical and clinical data from all three programs in the coming months.

Benny Sørensen, MD, PhD, Chief Executive Officer, Hemab Therapeutics

Not in the filing

stated, not guessed
  • No financial guidance (revenue, operating expense, tax or margin outlook) is provided in the filing.
  • No prior-year or prior-quarter percentage changes are printed for any metric; yoy_change and qoq_change are null throughout.
  • Prior-quarter (June 30, 2026) comparatives are printed only for cash, cash equivalents and marketable securities.
  • No prior-year (September 30, 2025) balance sheet figures are provided; balance sheet comparatives are as of December 31, 2025.
  • No segment or revenue disclosure; the company reports no revenue line in the filing.
  • No prior outlook was provided, so vs_prior_guidance is empty.
  • No share repurchase, dividend or other capital return figures are printed.
  • No headline figure for the change in cash and marketable securities as a percentage or dollar amount is printed; only the two period-end balances appear.
  • No explanation is given for the increase in interest income.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about COAG earnings dates

When is Hemab Therapeutics Holdings's next earnings date?
AlphAI has no date for COAG yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.